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Topoisomerase I (Topo I) is known as a target for chemotherapy in advanced or recur-
rent colorectal cancer.  In order to prolong the survival of patients with colorectal cancer 
or to prevent ineffective chemotherapy, we evaluated clinicopathological characteristics 
of Topo I protein in colorectal cancer.  Also, we estimated whether Topo I protein ex-
pression of primary tumors could be a parameter for chemosensitivity of Topo I inhibi-
tor in patients with cancer recurrence.  Immunohistochemical detection of Topo I pro-
tein was performed in 104 surgically obtained specimens.  Topo I protein was detected 
in 45 of 104 patients (43.2%).  Topo I protein expression closely correlated with tumor 
progression, histpathological differentiation and poor prognosis of patients.  Sixteen 
patients with recurrent cancer had been treated with Topo I inhibitor.  Topo I inhibi-
tor significantly prolonged the survival of 12 patients who had Topo I-positive primary 
tumors.  Topo I protein expression in colorectal cancer may be a biological marker for 
chemosensitivity of tumors against Topo I inhibitors.
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DNA topoisomerase I (Topo I) belongs to the 
DNA topoisomerase multimember family, which 
is essential for DNA topology modulation.  Topo 
I transiently cleaves one strand of DNA, allowing 
relaxation of the supercoiled DNA.  This process 
is important in cell replication, translation, recom-
bination and repair (Gupta et al., 1995).  Through 
Western and Northern blotting, Topo I protein 
and mRNA level were found to be more abundant 
in several human tumors than in normal tissues 
(Husain et al., 1994; Rowinsky et al., 1994; van 
der Zee et al., 1994; Giaccone et al., 1995). 
     Topo I is also a target for anticancer drugs, 
camptothecin and its derivatives (O’Leary and 
Muggia, 1998).  Topo I-inhibiting drugs interfere 
with Topo I function by binding to Topo I at its 
active site, and prevent re-ligation of the DNA 
strand (Goldwassew et al., 1995).  Camptothecin 
inhibits Topo I by forming stable Topo I–DNA 
cleavage complexes, and is specifically cytotoxic 
for S-phase cells (Hsiang et al., 1989). In vitro, 
tumor cells with a high level of Topo I protein 
respond better to Topo I inhibitors (Staley et al., 
1999).
     CPT-11, a derivative of camptothecin, has been 
used as one of the key drugs for treating colorec-
tal cancer (Paradiso et al., 2004; Vallböhmer et 
al., 2006).  In the last few years, it has been shown 
that when used in combination with 5-fluoroura-
cil and leucovorin, both CPT-11 and oxaliplatin 
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treatments demonstrated significant improvement 
in the clinical outcome of patients with advanced 
colorectal cancer (Doillard et al., 2000; de Gra-
mont et al., 2000).  However, response rates for 
these chemotherapeutic regimens still remain 
about 40% to 50%.  In the present study, we in-
vestigated the clinicopathological characteristics 
of colorectal tumors with Topo I protein expres-
sion.  Also, we analyzed Topo I protein expression 
in primary tumors could be a biomarker of che-
mosensitivity for recurrent patients or not. 
 
 
Materials and Methods
Tumor samples
 
We obtained tumors and non-cancerous nor-
mal mucosa from 104 patients who underwent 
colorectal resection between 1992 and 2001. 
Samples were collected immediately after sur-
gical resection of specimens.  The tissues were 
fixed in 10% buffered formalin and embedded in 
paraffin.  Four micrometer histological sections 
were destined to specific immunohistochemical 
determinations. 
 
Immunohistochemistry
 
After paraffin-embedded sections on the slides 
were dewaxed and rehydrated gradually with 
graded alcohols, antigen retrieval was performed 
by autoclaving in 10 mol citrate buffer for 30 min. 
Endogenous peroxidase activity was blocked by 
methanol and 0.3% hydrogen peroxide.  Slides 
were then incubated with primary anti Topo I 
monoclonal antibody (Clone 1D6, 1:50 dilution, 
Novocastra Laboratories, Newcastle, United 
Kingdom) for 1 h at room temperature.  After in-
cubation, the specimens were washed twice with 
phosphate-buffered saline solution (pH 7.6) and 
processed with the streptavidin-biotin peroxidase 
method according to the manufacturer’s recom-
mendations. The slides were then incubated in di-
aminobenzidine tetrahydrochloride and hydrogen-
peroxide chromogen substrate for 10 min at room 
temperature, washed in running water for 2 to 
3 min, counterstained in Mayer’s haematoxylin. 
Normal tonsil tissue was used as a positive con-
trol.  It is known that normal tonsil tissue is well 
stained by immunohistochemistry which uses 
Topo I antibody (Rasheed and Rubin, 2003).  
 
Scoring system
 
Tumor cells expressing Topo I immunoreactivity 
were quantified by 2 independent observers who 
evaluated at least 1,000 neoplastic cells in con-
secutive areas of neoplastic tissues.  If there was 
a Topo I-positive cell in the tumor, the sample 
was classified as “positive”.  If there were no Topo 
I-positive cells, the sample was classified as “neg-
ative” (Paradiso et al., 2004).
 
Patients
 
Clinicopathological findings of colorectal cancer 
were defined according to Dukes’ classification 
(Dukes and Bussey, 1958).  In all 104 patients, 
curative colorectal resection was performed be-
tween 1992 and 2001 at Tottori University Hospi-
tal.  Patients agreed to the use of their tissues by 
informed consent.  None of the patients received 
preoperative chemotherapy, and all were followed 
until December 2006. The types of cancer recur-
rence were established by computed tomography, 
performed at least twice a year. 
 
Statistical analysis
 
The chi-square test was used to compare the 
differences between the 2 groups.  The overall 
and disease-free survivals were estimated using 
Kaplan-Meier’s method and compared using a 
2-sided log rank test. Cox’s proportional hazards 
regression model was used to estimate the predic-
tive power of Topo I protein expression on clinical 
outcome.  Two-sided tests were computed, and P < 
0.05 was considered statistically significant. 
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Results
 
Topo I expression in tumors and in non-
cancerous tissues
 
Topo I protein expression was not detected in 
normal colorectal mucosa.  But it was detected 
in normal cells in basal layer of the skin adjacent 
to rectal cancer of patiens who had undergone 
amputation of the rectum (Fig. 1).  Topo I immu-
nostaining was mainly located in the nucleus of 
cancer cells (Fig. 2).
Fig. 2.  Immunohistochemical topoisomerase I protein expression in advanced colorectal cancer.  Strong nuclear ex-
pression of the protein is noted. Bar = 200 μm.  
Fig. 1.  Immunohistochemical topoisomerase I protein expression in normal colorectal mucosa adjacent to tumor (A) 
and in normal skin (B).  Bar = 200 μm.
A B
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Correlation with Topo I protein expression 
and clinicopathological findings of patients
 
Topo I protein expression was detected in 45 of 
104 patients (43.2%).  Topo I protein expression 
was more frequently detected in moderately dif-
ferentiated type or poorly differentiated type 
colorectal carcinoma than in well-differentiated 
carcinoma (Table 1).  Moreover, Topo I was posi-
tive in only 12 of 41 patients (29.3%) in Dukes’ 
A and B, while in 33 of 63 patients (52.4%) in 
Dukes’ C (Table 1). 
 
Topo I protein expression and prognosis of 
patients
 
The overall and disease-free 5-year survival rates 
of 104 patients with colorectal cancer were 64.9% 
and 75.5%, respectively.  The disease-free 5-year 
survival rate of 50 patients with moderately dif-
ferentiated or poorly differentiated carcinoma 
(63.6%) was lower than that of 54 patients with 
well differentiated carcinoma (86.4%, P = 0.01). 
And the disease-free 5-year survival rate of 63 pa-
tients in Dukes’ C (64.4%) was lower than that of 
41 patients in Dukes’ A and B (94.3%, P = 0.002). 
Moreover, when the 104 patients were divided 
into two sub-groups according to their immuno-
histochemical findings, the disease-free 5-year 
survival rate of the 45 Topo I-positive patients 
(62.7%) was significantly lower than that of the 59 
Topo I-negative patients (84.3%, P = 0.005, Fig. 3). 
     In order to understand whether Topo I pro-
tein expression is one of the prognostic factors of 
patients with colorectal cancer or not, variables 
(histological type, Dukes’ classification, Topo I 
protein expression) were analyzed by Cox’s pro-
portional hazards regression model.  Analysis 
determined that Topo I protein expression was not 
a prognostic factor independent from Dukes’ clas-
sification (Table 2). 
 
Topo I protein expression of tumors and ef-
fectiveness of adjuvant chemotherapy in 
patients with Dukes’ C carcinoma
 
Out of the 63 Dukes’ C patients, 47 were treated 
with 5-fluorouracil-based chemotherapy post-
operatively.  An oral dose of 600 mg/day of 
1-(2-tetrahydrofuryl)-5-fluorouracil/uracil (1:4) 
(UFT; Taiho Pharmaceutical, Tokushima, Japan) 
was administered to these patients for at least 1 
year.  Postoperative chemotherapy was not per-
formed on 13 patients because of advanced age 
Fig. 3.  The disease-free 5-year survival curve of 45 
topoisomerase I (Topo I)-positive patients (dotted line) 
is significantly lower than that of 59 Topo I-negative pa-
tients (solid line) (P = 0.005).  [  ], number of patients.
Table 1.  Topoisomerase I expression and clinicopathological findings
 Number of Topoisomerase I 
 patients  Negative Positive     P
Location of tumor Colon 55 29 26 
0.383
  Rectum 49 30 19
Histopathology Well-differentiated type 54 39 15 
0.001
  Moderately or poorly differentiated type 50 20 30
Dukes’ classification A or B 41 29 12 
0.020
  C 63 30 33
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Table 2.  Multivariate survival analysis in patients with colorectal cancer
                 Variable  Hazard ratio 95% Confidential interval P
Histological type of tumors 
 Moderately and poorly differentiated types  1.379 0.548– 3.467 0.495
    versus well-differentiated types
Dukes’ classification 
 C versus A and B 3.822 1.307–14.09 0.044
Topoisomerase I protein expression
 Positive versus negative 2.007 0.908– 4.937  0.083 
Table 3.  Survival time just after starting CPT-11 
chemotherapy in 16 patients with recurrent 
colorectal cancer
  50%
 Number Survival
 of  period†
 patients (month)   P
Topoisomerase I-negative  4  4  
0.041
Topoisomerase I-positive 12 12
† After starting chemotherapy.
(over 75) and 3 patients refused postoperative 
chemotherapy.  At the end of 2006, 23 Dukes’ 
C patients died from cancer recurrence.  Fifteen 
were in the chemotherapy group (32%, 15/47) 
and 8 were in the non-chemotherapy group (50%, 
8/16). Thus, 5-fluorouracil-based postoperative 
chemotherapy reduced the percentage of cancer 
recurrence from 50% to 32% in Dukes’ C patients 
(P = 0.2). 
 Among the 23 Dukes’ C patients who died 
from cancer recurrence, 16 were treated with 
Topo I inhibitor (CPT-11) just after detection of 
the recurrence.  We observed that among the 16, 
12 had Topo I-positive primary tumors, while 4 
had Topo I-negative primary tumors.  The sur-
vival periods just after the start of CPT-11 che-
motherapy ranged from 2 to 43 months.  Of these 
16 patients, CPT-11 chemotherapy prolonged the 
survival of 12 patients who had Topo I-positive 
primary tumors over the 4 patients who had Topo 
I-negative primary tumors (Table 3). 
 
Discussion
 
It is known that Topo I expression is not ob-
served in normal colon tissue, but we found Topo 
I-positive cells in basal cell layer of normal skin 
adjacent to rectal cancer.  Bauman et al. (1997) 
and Hafian et al. (2004) reported that the expres-
sion of Topo I and Topo II protein were detected 
in normal tissue with proliferating cells including 
normal tonsil and normal skin.  So, closed correla-
tion between Topo I protein expression and cell 
proliferative activity is thought to be possible.  In 
this study, we demonstrated the frequent occur-
rence of Topo I expression in surgically resected 
colorectal cancer (43.2%).  We found that the 
percentage of patients who had Topo I-positive tu-
mors was much higher in Dukes’ C than in Dukes’ 
A and B.  Moreover, Topo I protein expression was 
more frequently detected in moderately or poorly 
differentiated adenocarcinomas than in well differ-
entiated carcinomas.  These findings indicate that 
Topo I expression closely correlated with tumor 
progression and histopathological differentiation 
in colorectal cancer.  Also in human sarcomas, the 
incidence of detectable Topo I protein expression 
increased with tumor progression (Caleman et al., 
2002).  However, Staley et al. (1999) reported no 
correlation between Topo I expression and Dukes’ 
classification in 29 patients with colorectal cancer. 
But the number of patients in their study was too 
small to elucidate a clear correlation between Topo 
I protein expression and tumor progression in 
colorectal cancer.  Further investigation is needed.
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 We found that the 5-fluorouracil-based post-
operative chemotherapy prolonged the survival of 
patients with Dukes’ C colorectal cancer instead 
of Topo I protein expression of tumors.  Recently, 
Topo I inhibitors have frequently been used in 
the treatment of advanced or recurrent colorectal 
cancers (Paradiso et al., 2004). But correlation 
between clinical effectiveness of Topo I inhibitors 
and tumor expression of Topo I protein has not 
been well studied in human colorectal cancer pa-
tients.  In our study, we found that when CPT-11 
chemotherapy had been used for patients with 
recurrent tumors, the survival periods of patients 
who had Topo I-positive primary tumors were 
significantly prolonged than those of patients who 
had Topo I-negative primary tumors.  In vitro, it 
has been shown that tumors with a higher level of 
Topo I protein responded to Topo I inhibitors, but 
RNA expression was not predictive for the anti-
proliferative effect of Topo I inhibitors (Mcleod 
et al., 1996; Jansen et al., 1997). However, ATP-
binding cassette transporters called ABCG2 or 
carboxilesterases have been reported to correlate 
with tumor sensitivity against Topo I inhibitors 
(Pavillard et al., 2002; Sanghani et al., 2003; Wi-
erdl et al., 2003; Candeil et al., 2004). In order to 
prolong the survival of patients with advanced or 
recurrent colorectal cancer or to prevent ineffec-
tive chemotherapy for such patients, clinical im-
portance of Topo I protein expression in colorec-
tal cancer, especially sensitivity of tumors to Topo 
I inhibitors, should be investigated extensively. 
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